Dopamine Transporter Polymorphisms and rIsperidone Response in CHinese Schizophrenia Patients: An Association Study

• Heck AH , HaffmansPM, de Groot IW, Hoencamp E: Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr. Res.46, 97–105 (2000).
   PubMed Web of Science ®Google Scholar
• Csernansky JG , SchuchartEK: Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.CNS Drugs16, 473–484 (2002).
   PubMed Web of Science ®Google Scholar
• Riedel M , SchwarzMJ, StrassnigM et al.: Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci.255, 261–268 (2005).
   PubMed Web of Science ®Google Scholar
• Xing Q , GaoR, LiH et al.: Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics7, 987–993 (2006).
   PubMed Web of Science ®Google Scholar
• Leysen JE , JanssenPM, MegensAA, SchotteA: Risperidone: a novel antipsychotic with balanced serotonin–dopamine antagonism, receptor occupancy profile, and pharmacologic activity.J. Clin. Psychiatry55(Suppl.), 5–12 (1994).
   PubMed Web of Science ®Google Scholar
• Yamanouchi Y , IwataN, SuzukiT, KitajimaT, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J.3, 356–361 (2003).
   PubMed Web of Science ®Google Scholar
• Xing Q , QianX, LiH et al.: The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int. J. Neuropsychopharmacol.10, 631–637 (2007).
   PubMed Web of Science ®Google Scholar
• Riddle EL , FleckensteinAE, HansonGR: Role of monoamine transporters in mediating psychostimulant effects.AAPS J.7, E847–E851 (2005).
   PubMed Web of Science ®Google Scholar
• Sotnikova TD , BeaulieuJM, Gainetdinov RR, Caron MG: Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. CNS Neurol. Disord. Drug Targets5, 45–56 (2006).
   PubMedGoogle Scholar
• Bannon MJ , MichelhaughSK, WangJ, SacchettiP: The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders.Eur. Neuropsychopharmacol.11, 449–455 (2001).
   PubMed Web of Science ®Google Scholar
• Ase AR , AmdissF, HebertC, HuangN, van Gelder NM, Reader TA: Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin 1A receptors. J. Neural Transm.106, 75–105 (1999).
   PubMed Web of Science ®Google Scholar
• King N , BassettAS, HonerWG, Masellis M, Kennedy JL: Absence of linkage for schizophrenia on the short arm of chromosome 5 in multiplex Canadian families. Am. J. Med. Genet.74, 472–474 (1997).
   PubMed Web of Science ®Google Scholar
• Grunhage F , SchulzeTG, MullerDJ et al.: Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol. Psychiatry5, 275–282 (2000).
   PubMed Web of Science ®Google Scholar
• Kawarai T , KawakamiH, YamamuraY, NakamuraS: Structure and organization of the gene encoding human dopamine transporter.Gene195, 11–18 (1997).
   PubMed Web of Science ®Google Scholar
• Greenwood TA , KelsoeJR: Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene.Genomics82, 511–520 (2003).
   PubMed Web of Science ®Google Scholar
• Keikhaee MR , FadaiF, SargolzaeeMR, JavanbakhtA, NajmabadiH, OhadiM: Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder.Am. J. Med. Genet. B Neuropsychiatr. Genet.135, 47–49 (2005).
   Google Scholar
• Ohadi M , ShiraziE, TehranidoostiM et al.: Attention-deficit/hyperactivity disorder (ADHD) association with the DAT1 core promoter -67 T allele. Brain Res.1101, 1–4 (2006).
   PubMed Web of Science ®Google Scholar
• Khodayari N , GarshasbiM, FadaiF et al.: Association of the dopamine transporter gene (DAT1) core promoter polymorphism -67T variant with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.129, 10–12 (2004).
   Google Scholar
• Seeman P , NiznikHB: Dopamine receptors and transporters in Parkinsons‘ disease and schizophrenia.FASEB J.4, 2737–2744 (1990).
   PubMed Web of Science ®Google Scholar
• Kirley A , LoweN, HawiZ et al.: Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet.121, 50–54 (2003).
   Web of Science ®Google Scholar
• Roman T , RohdeLA, HutzMH: Polymorphisms of the dopamine transporter gene: influence on response to methylphenidate in attention deficit-hyperactivity disorder.Am. J. Pharmacogenomics4, 83–92 (2004).
   PubMedGoogle Scholar
• Kim JY , JungIK, HanC et al.: Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry Clin. Neurosci.59, 183–188 (2005).
   PubMed Web of Science ®Google Scholar
• Kay SR , FiszbeinA, OplerLA: The positive and negative syndrome scale (PANSS) for schizophrenia.Schizophr. Bull.13, 261–276 (1987).
   PubMed Web of Science ®Google Scholar
• LLerena A , BereczR, DoradoP et al.: Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.783, 213–219 (2003).
   PubMed Web of Science ®Google Scholar
• Stephens M , DonnellyP: A comparison of bayesian methods for haplotype reconstruction from population genotype data.Am. J. Hum. Genet.73, 1162–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Faul F : G*Power 3, a flexible statistical power analysis program for the social, behavioral, and biomedical sciences.Behav. Res. Methods39, 175–191 (2007).
   PubMed Web of Science ®Google Scholar
• Bannon MJ , MichelhaughSK, WangJ, SacchettiP: The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders.Eur. Neuropsychopharmacol.11, 449–455 (2001).
   PubMed Web of Science ®Google Scholar
• Bellgrove MA , HawiZ, KirleyA, Fitzgerald M, Gill M, Robertson IH: Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Neuropsychopharmacology30, 2290–2297 (2005).
   PubMed Web of Science ®Google Scholar
• Heinz A , GoldmanD, JonesDW et al.: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology22, 133–139 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobsen LK , StaleyJK, ZoghbiSS et al.: Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am. J. Psychiatry157, 1700–1703 (2000).
   PubMed Web of Science ®Google Scholar
• Fuke S , SuoS, TakahashiN, KoikeH, SasagawaN, IshiuraS: The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression.Pharmacogenomics J.1, 152–156 (2001).
   PubMedGoogle Scholar
• Martinez D , GelernterJ, Abi-DarghamA et al.: The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology24, 553–560 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang ML , YuanGZ, YaoJJ et al.: Associations between six functional genes and schizophrenia. Zhonghua Yi. Xue. Yi. Chuan Xue. Za Zhi.20, 69–71 (2003).
   PubMedGoogle Scholar
• Gamma F , FaraoneSV, GlattSJ, YehYC, TsuangMT: Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene.Schizophr. Res.73, 55–58 (2005).
   PubMed Web of Science ®Google Scholar
• Kamatani N , SekineA, KitamotoT et al.: Large-scale single-nucleotide polymorphism (SNP) and haplotype analyses, using dense SNP Maps, of 199 drug-related genes in 752 subjects: the analysis of the association between uncommon SNPs within haplotype blocks and the haplotypes constructed with haplotype-tagging SNPs. Am. J. Hum. Genet.75, 190–203 (2004).
   PubMed Web of Science ®Google Scholar
• Rubie C , SchmidtF, KnappM et al.: The human dopamine transporter gene: the 5´-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample. Neurosci. Lett.297, 125–128 (2001).
   PubMed Web of Science ®Google Scholar
• Greenwood TA , SchorkNJ, EskinE, Kelsoe JR: Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol. Psychiatry11, 125–133 (2006).
   PubMed Web of Science ®Google Scholar
• Kelada SN , Costa-MallenP, CheckowayH et al.: Dopamine transporter (SLC6A3) 5´ region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinsons‘ disease. Pharmacogenet. Genomics15, 659–668 (2005).
   PubMed Web of Science ®Google Scholar
• Gentile S : Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis.Drug Saf.29, 303–319 (2006).
   PubMed Web of Science ®Google Scholar

Websites

• Calculation of Chi-square test for deviation from Hardy–Weinberg equilibrium. www.kursus.kvl.dk/shares/vetgen/_Popgen/genetik/applets/kitest.htm
   Google Scholar
• Simple Interactive Statistical Analysis (SISA) http://home.clara.net/sisa/bonhlp.htm
   Google Scholar